SUBSCRIBE
SUBSCRIBE
News   Drug Development

ImmuPharma plc CEO Slams Stock Plunge After Drug Trial

November 19, 2009 | 
1 min read

Bookmark and Share

Reuters -- The head of lupus specialist ImmuPharma said mid-stage trial results for its lead drug were encouraging and should not have prompted a 19 percent drop in the share price on Thursday.

Clinical research Phase II
MORE ON THIS TOPIC
Heart human anatomy anatomical pottery neutral backgrounds soft tones beige brown background 3d illustration render digital rendering
Cardiovascular disease
Marea Posts Positive Phase II Data for Remnant Cholesterol Lowering mAb
January 10, 2025
 · 
1 min read
 · 
Kate Goodwin
Sign in front of Pfizer in Quebec, Canada
Bladder cancer
Pfizer’s Subcutaneous PD-1 Blocker Aces Phase III in Bladder Cancer, Carves Niche Versus Keytruda
January 10, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Eli Lilly's headquarters in Indianapolis
Collaboration
Lilly Makes $780M+ IPF Play with Mediar Partnership
January 10, 2025
 · 
2 min read
 · 
Tristan Manalac
Conceptual business illustration of upcoming business problem metaphor with falling domino and businessman silhouette. Minimalistic vector eps 10 illustration
ALS
HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail
January 10, 2025
 · 
5 min read
 · 
Heather McKenzie